Recerca

Àrea 5

Fisiopatologia i bases moleculars en hematologia

Factor d'impacte: mitjana: 6.88, total: 247.71

Articles de l'any 2010
Original
  • Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma

    Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, Camacho F, Bea S, Hartmann E, Amador V, Hernandez L, Agostinelli C, Sargent RL, Rozman M, Aymerich M, Colomer D, Villamor N, Swerdlow SH, Pileri SA, Bosch F, Piris MA, Montserrat E, Ott G, Rosenwald A, Lopez-Guillermo A, Jares P, Serrano S, Campo E
    CANCER RES. 2010; 70: 1408-1418. IF: 7.543

  • A Somatic NLRP3 Mutation as a Cause of a Sporadic Case of Chronic Infantile Neurologic, Cutaneous, Articular Syndrome/Neonatal-Onset Multisystem Inflammatory Disease Novel Evidence of the Role of Low-Level Mosaicism as the Pathophysiologic Mechanism Under

    Arostegui JI, Saldana MDL, Pascal M, Clemente D, Aymerich M, Balaguer F, Goel A, DelCastillo CF, Rius J, Plaza S, Robledillo JCL, Juan M, Ibanez M, Yague J
    ARTHRITIS RHEUM-US. 2010; 62: 1158-1166. IF: 7.332

  • In vitro and In vivo Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts

    Mollinedo F, DeLaIglesia-Vicente J, Gajate C, DeMendoza AEH, Villa-Pulgarin JA, DeFrias M, Roue G, Gil J, Colomer D, Campanero MA, Blanco-Prieto MJ
    CLIN CANCER RES. 2010; 16: 2046-2054. IF: 6.747

  • Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group

    Cervantes F, Lopez-Garrido P, Montero MI, Jonte F, Martinez J, Hernandez-Boluda JC, Calbacho M, Sureda A, Perez-Rus G, Nieto JB, Perez-Lopez C, Roman-Gomez J, Gonzalez M, Pereira A, Colomer D
    HAEMATOL-HEMATOL J. 2010; 95: 1317-1324. IF: 6.416

  • Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior

    Gine E, Martinez A, Villamor N, Lopez-Guillermo A, Camos M, Martinez D, Esteve J, Calvo X, Muntanola A, Abrisqueta P, Rozman M, Rozman C, Bosch F, Campo E, Montserrat E
    HAEMATOL-HEMATOL J. 2010; 95: 1526-1533. IF: 6.416

  • Oligonucleotide Array-CGH Identifies Genomic Subgroups and Prognostic Markers for Tumor Stage Mycosis Fungoides

    Salgado R, Servitje O, Gallardo F, Vermeer MH, Ortiz-Romero PL, Karpova MB, Zipser MC, Muniesa C, Garcia-Muret MP, Estrach T, Salido M, Sanchez-Schmidt J, Herrera M, Romagosa V, Suela J, Ferreira BI, Cigudosa JC, Barranco C, Serrano S, Dummer R, Tensen CP, Sole F, Pujol RM, Espinet B
    J INVEST DERMATOL. 2010; 130: 1126-1135. IF: 5.543

  • Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells

    Lopez-Royuela N, Perez-Galan P, Galan-Malo P, Yuste VJ, Anel A, Susin SA, Naval J, Marzo I
    BIOCHEM PHARMACOL. 2010; 79: 1746-1758. IF: 4.254

  • Folliculotropic mycosis fungoides: Clinicopathological features and outcome in a series of 20 cases

    Muniesa C, Estrach T, Pujol RM, Gallardo F, Garcia-Muret P, Climent J, Servitje O
    J AM ACAD DERMATOL. 2010; 62: 418-426. IF: 4.105

  • Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era

    Gutierrez-Garcia G, Colomo L, Villamor N, Arenillas L, Martinez A, Cardesa T, Garcia-Herrera A, Setoain X, Rodriguez S, Ghita G, Abrisqueta P, Gine E, Bosch F, Campo E, Montserrat E, Lopez-Guillermo A
    LEUKEMIA LYMPHOMA. 2010; 51: 1225-1232. IF: 2.397

  • Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?

    Costa D, Valera S, Carrio A, Arias A, Munoz C, Rozman M, Belkaid M, Coutinho R, Nomdedeu B, Campo E
    LEUKEMIA RES. 2010; 34: 1437-1441. IF: 2.358

  • Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures

    DeLarrea CF, Rosinol L, Cibeira MT, Rozman M, Rovira M, Blade J
    EUR J HAEMATOL. 2010; 85: 448-451. IF: 2.345

  • Epidemiology of Rare Anaemias in Europe

    Gulbis B, Eleftheriou A, Angastiniotis M, Ball S, Surralles J, Castella M, Heimpel H, Hill A, Corrons JLV
    ADV EXP MED BIOL. 2010; 686: 375-396. IF: 2.02

  • Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

    White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Wang YL, Branford S, Muller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, ElHousni H, Jones D, Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ESK, Press RD, Romeo G, Wang LH, Zoi K, Hughes T, Saglio G, Hochhaus A, Goldman JM, Metcalfe P, Cross NCP
    BLOOD. 2010; 116: 0-0. IF: 10.555

  • The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate-risk cytogenetics is dependent on NPM1 mutational status

    Diaz-Beya M, Rozman M, Pratcorona M, Torrebadell M, Camos M, Aguilar JLI, Esteve J
    BLOOD. 2010; 116: 6147-6148. IF: 10.555

Revisió
  • Cell Death Targeting Therapies in B Lymphoid Malignancies

    Saborit-Villarroya I, Roue G, Lopez-Guerra M, Alonso R, Xargay-Torrent S, Rosich L, Colomer D
    CURR DRUG TARGETS. 2010; 11: 769-780. IF: 3.932

  • NF-kappa B as a therapeutic target in chronic lymphocytic leukemia

    Lopez-Guerra M, Colomer D
    EXPERT OPIN THER TAR. 2010; 14: 275-288. IF: 3.713

Tornar